Repare Therapeutics Acquired by XenoTherapeutics

Got story updates? Submit your updates here. ›

Repare Therapeutics Inc., a clinical-stage precision oncology company, has announced the completion of its acquisition by XenoTherapeutics, Inc., a Massachusetts-based non-profit biotechnology company. The acquisition was approved by Repare's shareholders and the Superior Court of Québec.

Why it matters

The acquisition of Repare Therapeutics by XenoTherapeutics represents a significant milestone for the precision oncology field, as Repare has developed highly targeted cancer therapies focused on genomic instability and DNA damage repair. The transaction will allow XenoTherapeutics to further advance Repare's clinical-stage pipeline, including RP-3467, a Phase 1 Polθ ATPase inhibitor, and RP-1664, a Phase 1 PLK4 inhibitor.

The details

Under the terms of the acquisition, Repare shareholders will receive a cash payment of approximately US$2.20 per common share, as well as one non-transferable contingent value right (CVR) per common share. The CVRs represent the right to receive a pro rata portion of potential future payments, subject to the terms and conditions of the CVR agreement. As a result of the completion of the acquisition, Repare's common shares are expected to cease trading on the Nasdaq Global Select Market, and the company will subsequently file a Form 15 with the SEC to request suspension of its reporting obligations.

• The acquisition was approved by Repare's shareholders on January 16, 2026.
• The final order approving the acquisition was issued by the Superior Court of Québec on January 23, 2026.
• The acquisition was completed on January 28, 2026.

What’s next

Repare's common shares are expected to cease trading on the Nasdaq Global Select Market on or about January 28, 2026, and the company will subsequently file a Form 15 with the SEC requesting suspension of its reporting obligations under the U.S. Securities Exchange Act of 1934.